Cargando…
Estimating recurrences prevented and costs avoided with atezolizumab in early non‐small cell lung cancer in the United States
BACKGROUND: Recurrence of early‐stage non‐small cell lung cancer (eNSCLC) is associated with significant mortality and costs. Atezolizumab (ATZ) was recently approved as adjuvant treatment following resection and platinum‐based chemotherapy for adults with stage II‐IIIA NSCLC with PD‐L1 expression ≥...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067035/ https://www.ncbi.nlm.nih.gov/pubmed/36420712 http://dx.doi.org/10.1002/cam4.5462 |